ArticleFrontiers in oncology2025
Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, has significantly improved the survival rates of patients with locally advanced lung cancer. This article reports on a case of stage IVB (cT2bN1M1c1) non-small cell lung cancer (NSCLC) with brain metastases harboring compound mutations in epidermal growth factor receptor (EGFR) exon 21 Leu858Arg and mitogen-activated protein kinase 1 (MEK1) exon 3 lle112Thr and with a high program death ligand 1 (PD-L1) expression that successfully underwent radical lung cancer surgery following combined therapy. We report on a case of a 60-year-old man diagnosed preoperatively with stage IVB adenocarcinoma of the left upper lung (cT2bN1M1c1) who was diagnosed with multiple brain metastases. After multidisciplinary discussion, it was decided to administer targeted therapy with furmonertinib, chemotherapy with pemetrexed and lobaplatin, and immunotherapy with tislelizumab. Following 2 months of treatment, tumor assessment showed partial response (PR). After 11 months, assessment showed a PR of all lung lesions and complete response of the brain lesions, making the patient eligible for surgery. Finally, the patient underwent video-assisted thoracoscopic left upper lobectomy + mediastinal lymphadenectomy. Postoperative pathology confirmed complete response, and the patient continued adjuvant therapy with furmonertinib. For patients with metastatic advanced NSCLC, systemic treatment involving chemotherapy plus immunotherapy and targeted therapy is expected to become one of the options. Moreover, it is likely to achieve successful conversion surgery and further efficacy after combined therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.